ATE516353T1 - Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs - Google Patents

Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs

Info

Publication number
ATE516353T1
ATE516353T1 AT04743564T AT04743564T ATE516353T1 AT E516353 T1 ATE516353 T1 AT E516353T1 AT 04743564 T AT04743564 T AT 04743564T AT 04743564 T AT04743564 T AT 04743564T AT E516353 T1 ATE516353 T1 AT E516353T1
Authority
AT
Austria
Prior art keywords
treatment
rnai
cancer
drug
produce
Prior art date
Application number
AT04743564T
Other languages
English (en)
Inventor
Thomas Helleday
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516353(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Sheffield filed Critical Univ Sheffield
Application granted granted Critical
Publication of ATE516353T1 publication Critical patent/ATE516353T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
AT04743564T 2003-07-25 2004-07-23 Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs ATE516353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
PCT/GB2004/003235 WO2005012524A1 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE516353T1 true ATE516353T1 (de) 2011-07-15

Family

ID=27772701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743564T ATE516353T1 (de) 2003-07-25 2004-07-23 Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs

Country Status (18)

Country Link
US (5) US8859562B2 (de)
EP (1) EP1649017B2 (de)
JP (3) JP5519097B2 (de)
KR (1) KR101136702B1 (de)
CN (3) CN102935230B (de)
AT (1) ATE516353T1 (de)
AU (1) AU2004261779B2 (de)
BR (1) BRPI0412909B1 (de)
CA (1) CA2533423C (de)
DK (1) DK1649017T4 (de)
ES (1) ES2367433T5 (de)
GB (2) GB0317466D0 (de)
NO (1) NO338398B1 (de)
NZ (1) NZ545307A (de)
PL (1) PL1649017T5 (de)
PT (1) PT1649017E (de)
WO (1) WO2005012524A1 (de)
ZA (1) ZA200601386B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
EP1836320A2 (de) * 2005-01-07 2007-09-26 Arqule, Inc. Zusammensetzungen zur parp modulation und screening verfahren dafur
EP2319847A3 (de) 2005-01-19 2012-06-20 Eisai Inc. Diazabenzo[de]anthracen-3-on-Verbindungen und Verfahren zur Hemmung von PARP
EP1855676A4 (de) 2005-02-25 2008-05-21 Inotek Pharmaceuticals Corp Tetrazyklische amino- und carboxamidoverbindungen sowie verfahren zu ihrer verwendung
AU2006283078A1 (en) 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone Analogs and methods of use thereof
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
AU2007325900A1 (en) 2006-10-20 2008-06-05 Dnar, Inc. DNA damage repair inhibitors and methods for treating cancer
CA2674084C (en) * 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US8119654B2 (en) 2007-02-28 2012-02-21 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
GB0707556D0 (en) * 2007-04-19 2007-05-30 Isis Innovation Treatment for cancer
WO2008156172A1 (ja) 2007-06-20 2008-12-24 Saitama Medical University 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
PL2209375T3 (pl) 2007-10-03 2014-12-31 Eisai Inc Związki, kompozycje i metody stosowania inhibitorów PARP
JP5683261B2 (ja) 2008-03-11 2015-03-11 学校法人 埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
AU2009308423B2 (en) * 2008-10-24 2013-08-29 Magnachem International Laboratories, Inc. Method for screening for compounds selectively interacting with Rad9
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
SG189280A1 (en) * 2010-10-07 2013-05-31 Agency Science Tech & Res Parp-1 inhibitors
SG10201605814QA (en) 2011-07-22 2016-09-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
CA2864481C (en) * 2012-02-23 2020-07-14 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
IN2015MN00002A (de) 2012-07-09 2015-10-16 Lupin Ltd
US20160040155A1 (en) * 2013-04-16 2016-02-11 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
AU2014321200A1 (en) * 2013-09-23 2016-05-05 The University Of Chicago Methods and compositions relating to cancer therapy with DNA damaging agents
EP3102680B1 (de) * 2014-02-07 2018-12-19 VIB vzw Hemmung von neat1 zur behandlung von soliden tumoren
US9889141B2 (en) 2014-10-14 2018-02-13 Institute For Cancer Research Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
PL3325662T3 (pl) 2015-07-17 2024-02-26 Pacylex Pharmaceuticals Inc. Wyciszenie epigenetyczne nmt2
US20180282383A1 (en) * 2015-10-02 2018-10-04 University Of Copenhagen Small molecules blocking histone reader domains
ES2847252T3 (es) * 2016-02-22 2021-08-02 Caribou Biosciences Inc Procedimientos de modulación de resultados de reparación de ADN
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
CN107058233A (zh) * 2017-05-03 2017-08-18 上海长海医院 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法
CN108048465A (zh) * 2017-12-20 2018-05-18 李风玲 一种抑制PARP基因用于治疗乳腺癌的siRNA
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CN116234803A (zh) 2019-12-23 2023-06-06 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
KR20230002487A (ko) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114836472A (zh) * 2021-02-01 2022-08-02 中国人民解放军军事科学院军事医学研究院 PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用
BR112023020615A2 (pt) 2021-04-08 2023-12-19 Incozen Therapeutics Pvt Ltd Inibidores de poli(adp-ribose) polimerase
JP2024518509A (ja) 2021-05-18 2024-05-01 オンコニック セラピューティクス インコーポレイテッド Ｐａｒｐ阻害剤抵抗性癌治療剤
EP4433089A1 (de) * 2021-11-19 2024-09-25 Institut Curie Verfahren zur behandlung von hrd-krebs und brca-assoziiertem krebs
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (de) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolylderivate als dna-polymerase- theta-hemmer und verwendungen davon
EP4683630A1 (de) * 2023-03-21 2026-01-28 Institut Curie Vps4b-inhibitor zur verwendung in verfahren zur behandlung von hrd-krebs
WO2024194402A1 (en) * 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5098861A (en) 1991-01-08 1992-03-24 Unitrode Corporation Method of processing a semiconductor substrate including silicide bonding
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AU8784698A (en) * 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
HRP20010573B1 (en) * 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
AR030121A1 (es) * 2000-08-08 2003-08-13 Sanofi Aventis Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
EP1397350B1 (de) 2001-05-08 2007-02-28 Kudos Pharmaceuticals Limited Isochinolinon derivate als parp inhibitoren
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004008976A1 (en) 2002-07-19 2004-01-29 Osteotech, Inc. Chisels and procedure for insertion of spinal implant in a spinal disc space
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
US7176188B2 (en) * 2003-05-07 2007-02-13 UniversitéLaval Method of lethally sensitizing human and animal cells
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
ATE454893T1 (de) * 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer

Also Published As

Publication number Publication date
CA2533423A1 (en) 2005-02-10
ES2367433T5 (es) 2014-11-03
US8859562B2 (en) 2014-10-14
ES2367433T3 (es) 2011-11-03
BRPI0412909B1 (pt) 2022-04-12
CN1856313A (zh) 2006-11-01
US20070179160A1 (en) 2007-08-02
NO338398B1 (no) 2016-08-15
PL1649017T5 (pl) 2015-02-27
EP1649017B1 (de) 2011-07-13
PT1649017E (pt) 2011-09-30
JP2014001210A (ja) 2014-01-09
EP1649017A1 (de) 2006-04-26
GB0603874D0 (en) 2006-04-05
CN1856572B (zh) 2013-11-06
CN1856572A (zh) 2006-11-01
JP2012102099A (ja) 2012-05-31
EP1649017B2 (de) 2014-08-27
JP5848728B2 (ja) 2016-01-27
DK1649017T4 (da) 2014-12-01
GB2419882B (en) 2008-04-09
GB2419882A (en) 2006-05-10
KR20060052877A (ko) 2006-05-19
CN102935230A (zh) 2013-02-20
JP5547164B2 (ja) 2014-07-09
DK1649017T3 (da) 2011-10-17
US20150005327A1 (en) 2015-01-01
KR101136702B1 (ko) 2012-04-20
CN1856313B (zh) 2011-01-12
NO20060906L (no) 2006-04-25
WO2005012524A1 (en) 2005-02-10
HK1094006A1 (en) 2007-03-16
US20220062286A1 (en) 2022-03-03
US20200237762A1 (en) 2020-07-30
CA2533423C (en) 2014-07-22
CN102935230B (zh) 2016-08-10
AU2004261779B2 (en) 2008-07-24
AU2004261779A1 (en) 2005-02-10
HK1182016A1 (zh) 2013-11-22
JP5519097B2 (ja) 2014-06-11
JP2006528618A (ja) 2006-12-21
GB0317466D0 (en) 2003-08-27
PL1649017T3 (pl) 2011-12-30
ZA200601386B (en) 2007-04-25
BRPI0412909A (pt) 2006-09-26
US20180000822A1 (en) 2018-01-04
NZ545307A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
ATE516353T1 (de) Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
ATE555788T1 (de) Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
TW201712023A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
EA201270480A1 (ru) Новые соединения
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
NZ710443A (en) Method of identifying disease risk factors
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
EA201370139A1 (ru) Ингибиторы микро-рнк, содержащие закрытые нуклеотиды
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
EA201071307A1 (ru) Карбамоильные производные бициклических карбониламинопиразолов в качестве пролекарств
SG195127A1 (en) Methods of treating or preventing neurological diseases
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2011066082A3 (en) Markers associated with ribavirin-induced anemia
EP2216043A4 (de) Verwendung von induktormitteln gse24.2 zur herstellung pharmazeutischer zusammensetzungen zur behandlung von erkrankungen in zusammenhang mit zellseneszenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1649017

Country of ref document: EP